Collegium Pharmaceutical (NASDAQ:COLL) – Investment analysts at Piper Jaffray dropped their FY2021 earnings estimates for shares of Collegium Pharmaceutical in a report released on Wednesday, May 9th, according to Zacks Investment Research. Piper Jaffray analyst D. Amsellem now expects that the specialty pharmaceutical company will earn $2.06 per share for the year, down from their prior forecast of $2.32. Piper Jaffray has a “Buy” rating and a $33.00 price objective on the stock.
COLL has been the topic of a number of other research reports. BidaskClub lowered shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Friday, February 23rd. Zacks Investment Research raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $26.00 price objective on the stock in a research report on Monday, April 16th. ValuEngine raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. William Blair reissued an “outperform” rating on shares of Collegium Pharmaceutical in a research report on Thursday, March 8th. Finally, Needham & Company LLC boosted their price objective on shares of Collegium Pharmaceutical from $28.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, February 7th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Collegium Pharmaceutical has a consensus rating of “Buy” and an average price target of $30.83.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, May 9th. The specialty pharmaceutical company reported ($0.57) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.02). The company had revenue of $63.70 million during the quarter, compared to the consensus estimate of $51.92 million. Collegium Pharmaceutical had a negative net margin of 78.22% and a negative return on equity of 72.87%. The business’s quarterly revenue was up 2835.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.79) EPS.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Benjamin F. Edwards & Company Inc. raised its position in Collegium Pharmaceutical by 87.5% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock worth $138,000 after acquiring an additional 3,500 shares in the last quarter. Wellington Shields Capital Management LLC bought a new stake in Collegium Pharmaceutical during the first quarter worth $204,000. Stifel Financial Corp bought a new stake in Collegium Pharmaceutical during the first quarter worth $224,000. Acadian Asset Management LLC bought a new stake in Collegium Pharmaceutical during the fourth quarter worth $176,000. Finally, State Board of Administration of Florida Retirement System bought a new stake in Collegium Pharmaceutical during the first quarter worth $260,000. 85.97% of the stock is currently owned by hedge funds and other institutional investors.
In other Collegium Pharmaceutical news, Chairman Michael Thomas Heffernan sold 44,400 shares of the company’s stock in a transaction on Thursday, April 19th. The shares were sold at an average price of $26.00, for a total transaction of $1,154,400.00. Following the sale, the chairman now directly owns 545,893 shares of the company’s stock, valued at $14,193,218. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 25.76% of the company’s stock.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.